SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive, meme-like volatility and parabolic price action as retail traders and institutional flows surge ahead of the company's upcoming inclusion in the Nasdaq-100. Community sentiment is deeply polarized, with bulls chasing momentum fueled by AI-driven memory demand and rumors of a stock split, while skeptics warn of an overextended bubble nearing a potential distribution top.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a buyout or aggressive turnaround, fueled by persistent short interest and frustration over the board's delay in naming a permanent CEO. While some market participants see deep value in the brand's international expansion and high dividend yield, others remain skeptical, pointing to lackluster domestic performance and operational challenges.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to its recent award of over $4 million in U.S. government contracts, which investors view as a pivotal validation of its semiconductor and quantum materials technology. The community is actively debating the company's long-term potential to scale its proprietary platform while closely monitoring its ability to move from research-focused government projects to high-volume commercial manufacturing partnerships.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors react to bullish analyst upgrades, a major $151 billion defense contract, and strategic partnerships involving AI-driven network infrastructure and data centers. The community is actively discussing its long-term potential as a key player in the 6G and AI-RAN space, with many comparing its current trajectory to other optical powerhouses while debating the impact of increased institutional buying and recent technical breakouts.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and bullish sentiment driven by investor anticipation of a potential gamma squeeze as market makers move to hedge against heavy call option activity. The community is actively discussing the stock's role in the AI-driven optical interconnect sector, with many highlighting its potential as a critical, high-margin supplier within the broader data center infrastructure space.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and bearish sentiment as investors weigh concerns over massive AI-related capital expenditures, high debt levels, and recent layoffs against its ambitious cloud infrastructure expansion. While the community is deeply divided between long-term bulls highlighting substantial revenue backlogs and AI-driven growth potential versus skeptics wary of slowing enterprise software demand and valuation risks, the stock continues to face heavy selling pressure.

Maulcoin

Maulcoin is generating significant momentum as a community-driven project that is rallying its 'Mauler' base to push toward milestones like a million-dollar market cap. Participants are actively engaging on social platforms to boost visibility and drive growth, focusing on long-term holding and collective action to establish the token as a durable player in the meme coin space.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a meme-driven cultural asset that traces its roots back to a 2011 BitcoinTalk forum joke, with community members emphasizing its long history and parody status compared to newer meme coins. Investors are actively discussing whale accumulation and a 'billion-dollar' narrative, fueled by community efforts to establish the project as an enduring, ironic alternative to traditional crypto.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest positive late-stage trial results for their pancreatic cancer drug, daraxonrasib, which significantly improved patient survival rates compared to standard chemotherapy. The community is heavily focused on the drug's practice-changing clinical outcomes and the potential for the company to emerge as a dominant force in targeted oncology, fueling intense speculation regarding its long-term market valuation and buyout prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV

Elevate Capital Advisors LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 31.8% during the 4th quarter, according to its most recent 13F filing with the Securities...

Insider Selling: Roivant Sciences (NASDAQ:ROIV) CAO Sells 13,538 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Jennifer Humes sold 13,538 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37...

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know

Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV

Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 124.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities...

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP

Roivant Sciences and Priovant Therapeutics executives outlined an expansion of the brepocitinib development program into lichen planopilaris (LPP) and discussed newly released Phase 3 results for batoclimab in thyroid eye disease (TED), which failed to meet its primary endpoint.

Brepocitinib expand...

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint

Roivant Sciences (NASDAQ:ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brepocitinib into lichen planopilaris (LPP) and provided an update on a Phase III thyroid eye disease (TED) trial for batoclimab during a conference call hosted by the company.

Brepocitinib expands into l...

250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 250,468 shares of the company's stock, valued at a...

Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV

Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 11,507.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,937,112 shares of the company's s...

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendat...

Sanford C. Bernstein Begins Coverage on Roivant Sciences (NASDAQ:ROIV)

Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research note on Friday. They set an "outperform" rating and a $35.00 target price for the company...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Current Price	$28.71
Prev Close	$28.21
Open	$28.49
Dividend Yield	0.00%
50-Day Moving Average	$27.17
Beta	0.94
Avg. Volume	6.19M
PE Ratio	-24.14

52-Week High	$30.33
52-Week Low	$9.87
Market Capitalization	$20.19B
EPS (Annual)	-$0.2371
Price to Book	4.69
Revenue Per Employee	$38,737.33

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ROIV News

ROIVRoivant Sciences Ltd